Related references
Note: Only part of the references are listed.Automating drug discovery
Gisbert Schneider
NATURE REVIEWS DRUG DISCOVERY (2018)
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
David R. Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino et al.
LANCET ONCOLOGY (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves
David P. Enot et al.
ONCOIMMUNOLOGY (2018)
High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair
Marco E. Bianchi et al.
IMMUNOLOGICAL REVIEWS (2017)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Nasser Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
Qingsong Yin et al.
JOURNAL OF IMMUNOLOGY (2017)
Global survey of the immunomodulatory potential of common drugs
Gregory I. Vladimer et al.
NATURE CHEMICAL BIOLOGY (2017)
Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer
Coureche-Guillaume Kaderbhai et al.
ONCOIMMUNOLOGY (2017)
Progress towards a public chemogenomic set for protein kinases and a call for contributions
David H. Drewry et al.
PLOS ONE (2017)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
Chiara Pozzi et al.
NATURE MEDICINE (2016)
A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancer
Y. Ma et al.
ONCOGENE (2016)
Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer
Gautier Stoll et al.
ONCOIMMUNOLOGY (2016)
Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy
Heng Yang et al.
ONCOIMMUNOLOGY (2016)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Erika Vacchelli et al.
SCIENCE (2015)
Discordant Growth of Monozygotic Twins Star ts at the Blastocyst Stage: A Case Study
Laila Noli et al.
STEM CELL REPORTS (2015)
Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy
Kilian V. M. Huber et al.
NATURE (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Molecular Pathways: ROS1 Fusion Proteins in Cancer
Kurtis D. Davies et al.
CLINICAL CANCER RESEARCH (2013)
Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells
Yuting Ma et al.
IMMUNITY (2013)
ALK in Lung Cancer: Past, Present, and Future
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The secret ally: immunostimulation by anticancer drugs
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
An Immunosurveillance Mechanism Controls Cancer Cell Ploidy
Laura Senovilla et al.
SCIENCE (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
Laurie Menger et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody
Greta Garrido et al.
JOURNAL OF IMMUNOLOGY (2011)
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
Nicolas F. Delahaye et al.
NATURE MEDICINE (2011)
Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib
Vince D. Cataldo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Mickael Michaud et al.
SCIENCE (2011)
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death
Theocharis Panaretakis et al.
EMBO JOURNAL (2009)
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
Michel DuPage et al.
NATURE PROTOCOLS (2009)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
N Casares et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects
DA Tuveson et al.
CANCER CELL (2004)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
